Bivalirudin and Hirudin: How Peptide Anticoagulants Work
Anticoagulant peptides
Bivalirudin is a 20-amino-acid synthetic peptide that blocks thrombin, the enzyme at the centre of blood clotting, and it is modelled on hirudin, a protein from the medicinal leech. It is one of the clearest examples of a natural peptide being redesigned into a clinical anticoagulant, and its trial history is also a good lesson in how comparator choice changes what a result means.
What are hirudin and bivalirudin?
Hirudin comes from the medicinal leech, Hirudo medicinalis. The UniProt entry for hirudin variant-1 (P01050) describes a 65-amino-acid protein of about 6,970 Da, stabilised by three disulfide bonds (Cys6–Cys14, Cys16–Cys28 and Cys22–Cys39; see disulfide bonds in peptides) and carrying a sulfated tyrosine at position 63 in the leech-made form. It is described as a potent, thrombin-specific protease inhibitor that forms a stable, non-covalent complex with alpha-thrombin and blocks cleavage of fibrinogen.
Bivalirudin (formerly called hirulog) is a chemically synthesised 20-residue peptide designed in the same spirit: a much shorter molecule that keeps the thrombin-blocking behaviour of its natural parent. A 2019 study in the Journal of Clinical Pathology describes both hirudin and bivalirudin as bivalent direct thrombin inhibitors that bind the active site and exosite 1 of thrombin, hirudin irreversibly and bivalirudin reversibly.
How bivalirudin is studied to work
Thrombin has two functionally important regions: the catalytic active site that cuts fibrinogen into fibrin, and an anion-binding region called exosite 1 that docks substrates. A bivalent inhibitor is one molecule that occupies both. Unlike heparin, which works indirectly by boosting the plasma protein antithrombin, these peptides bind thrombin directly. Pharmacology reviews describe bivalirudin as having a predictable, dose-related anticoagulant effect and a low immunogenic profile, with dual elimination through proteolytic cleavage and renal clearance (Expert Review of Cardiovascular Therapy, 2010).
Reported effects in the research literature
Because bivalirudin acts directly on thrombin rather than through antithrombin, it has been studied as an alternative to heparin in settings where heparin has drawbacks. The 2010 pharmacology review notes its use in percutaneous coronary intervention (PCI), in cardiac and endovascular surgery, and frequently in the management of patients with heparin-induced thrombocytopenia (HIT), an immune reaction to heparin.
What the human evidence shows
Two large randomised trials illustrate why the comparator matters. In HORIZONS-AMI (Stone and colleagues, NEJM 2008), 3,602 patients with ST-elevation myocardial infarction undergoing primary PCI received either bivalirudin alone or heparin plus a glycoprotein IIb/IIIa inhibitor. At 30 days, net adverse clinical events were lower with bivalirudin (9.2% versus 12.1%; relative risk 0.76, 95% CI 0.63–0.92), driven by less major bleeding (4.9% versus 8.3%; relative risk 0.60, 95% CI 0.46–0.77).
VALIDATE-SWEDEHEART (Erlinge and colleagues, NEJM 2017) asked a different question. It randomised 6,006 patients (3,005 with STEMI and 3,001 with NSTEMI), mostly treated through the radial artery, to bivalirudin or to heparin alone, without planned glycoprotein IIb/IIIa inhibitors. At 180 days the composite of death, myocardial infarction or major bleeding occurred in 12.3% versus 12.8% (hazard ratio 0.96, 95% CI 0.83–1.10; P = 0.54), with consistent results in both STEMI and NSTEMI.
Read together, the trials show that the choice of comparator matters: a bleeding advantage seen against heparin plus a glycoprotein IIb/IIIa inhibitor was not seen against heparin alone in a largely radial-access population. We have deliberately not quoted figures from other trials we could not verify from primary sources.
Handling, storage and reconstitution (research context)
Synthetic peptides such as bivalirudin are supplied as lyophilised powders (see why peptides are freeze-dried) that must be reconstituted before use in a laboratory setting. The reconstitution calculator and concentration converter handle the concentration arithmetic, and our reconstitution guide and sterile technique guide cover practice. Always follow the manufacturer’s data sheet, and remember that units are not interchangeable with mL.
Cautions and considerations
Any anticoagulant carries a bleeding risk, and a bleeding-versus-clotting balance is exactly what the trials above measure. Bivalirudin is a prescription drug administered in hospital settings; nothing here is a recommendation to use, source or self-administer any anticoagulant. Kidney function affects how bivalirudin is cleared, which is one reason dosing is managed by clinicians.
Frequently asked questions
Is bivalirudin the same as hirudin?
No. Hirudin is a 65-residue natural protein from leeches; bivalirudin is a 20-residue synthetic peptide. Both are bivalent direct thrombin inhibitors, but hirudin binds irreversibly and bivalirudin reversibly.
How is bivalirudin different from heparin?
Heparin works indirectly by enhancing antithrombin. Bivalirudin binds thrombin directly, so it does not need antithrombin.
Why did two big trials give different answers?
They tested different comparators. HORIZONS-AMI compared bivalirudin with heparin plus a glycoprotein IIb/IIIa inhibitor; VALIDATE-SWEDEHEART compared it with heparin alone, mostly via radial access.
Is bivalirudin used in heparin-induced thrombocytopenia?
Pharmacology reviews report that it is frequently used in HIT management, in part because it has a low immunogenic profile compared with heparin.
References
- UniProt P01050 — Hirudin variant-1, Hirudo medicinalis
- Stone GW et al. Bivalirudin during primary PCI in acute myocardial infarction (HORIZONS-AMI). N Engl J Med 2008 (PMID 18499566)
- Erlinge D et al. Bivalirudin versus heparin monotherapy in myocardial infarction (VALIDATE-SWEDEHEART). N Engl J Med 2017 (PMID 28844201)
- Bivalirudin: a review of the pharmacology and clinical application. Expert Rev Cardiovasc Ther 2010 (PMID 21108549)
- Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin. J Clin Pathol 2019 (PMID 31366633)
- PubChem CID 16129704 — Bivalirudin
Informational only — not medical advice. This article is for educational purposes. It does not recommend, sell or instruct personal human use of any compound. Consult a qualified healthcare professional for any health decision. Content is intended for adults 21+. Verify scientific details against the primary sources cited.